高龄急性冠脉综合征的治疗进展

www.yongyao.net　　2009-9-28 10:11:48　　来源：　　责任编辑：

分享到：

[ 参考文献]
[ 1 ] 　梁　岩,朱　俊,谭慧琼,等. 中国地区非ST抬高急性冠脉综合征患者生存时间的影响因素分析[ J ]. 中华医学杂志, 2005, 85 (13) : 873.
[ 2 ] 　杨艳敏,朱　俊,谭慧琼,等. 中国ST段抬高的急性心肌梗死临床特征及治疗现状[ J ]. 中华医学杂志, 2005, 85 (31) : 2176.
[ 3 ] 　Jean2Marc B,Normand R, Thap HT, et al. Age2related differences in in2hosp italmortality and the use of thrombolytic therapy for acute myocardial infarction[ J ].CMAJ , 2001, 64 (9) : 1285-1290.
[ 4 ] 　BergerAK. Thrombolysis in elderly patientswith acute myocardial infarction[ J ]. AJGC, 2003, 12: 251-258.
[ 5 ] 　French JK. Which elderly patientswith cardiogenic shock should be treated with percutaneous coronary intervention [ J ] ? Am Heart J , 2004, 147 ( 6 ) : 1066-1070.
[ 6 ] 　Gibbons RJ , HolmesDR, Reeder GS, et al. Immediate angiop lasty compared with the administration of a thrombolystic agent followed by conservative treatment for myocardial infarction. TheMayo Coronary Care Unit and Catheterization Laboratory Group s[ J ]. N Engl J Med, 1993, 328 (10) : 685-691.
[ 7 ] 　Zijlastra F, de BoerMJ , Hoomtje JC, et al. A comparison of immediate coronary angiop lasty with intravenous strep tokinase in acute myocardial infarction [ J ]. NEngl J Med, 1993, 328 (100) : 680-684.
[ 8 ] 　BergerAK, Schulman KA, Gersh BJ , et al. Primary coronary angiop lasty vs thrombolysis for the management of acute myocardial infarction in elderly patients [ J ]. JAMA, 1999, 282 (4) : 341-348.
[ 9 ] 　Samaha EF, Kinnel SE, Kizer JR, et al. U sefulness of the TIM I risk score in p redicting both short2and long2term outcomes in the Veterans Affairs Non2Q2WaveMyocardial Infarction Strategies In2Hosp ital (VANQW ISH) Trial[ J ]. Am J Cardiol, 2002, 90 (9) : 922-926.
[ 10 ] 　Peterson E,Alexander K,Malenka DJ , et al. Multicenter experience in revascularization of very elderly [ J ]. Am Heart J , 2004, 148 (3) : 486-492.
[ 11 ] 　Klein LW, B lock P, B rindis RG, et al. Percutaneous coronary interventions in octogenarians in the American College of Cardiology National Cardiovascular Data Registry: development of a nomogram p redictive of in hosp ital mortality[ J ]. J Am Coll Cardiol, 2002, 40: 394-402.
[ 12 ] 　Gehanne A, Shayne A, Eltchaninoff H, et al. Interventricularmanagement of patients over the age of 75 with acute coronary syndromeswithout persistent ST elevation [ J ]. ArchMal CoeurVaiss, 2005, 98 (6) : 615-619.
[ 13 ] 　Bounhoure JP, Carrie D, Puel J. Coronary syndromes in the elderly [ J ]. Bull Acad NatlMed, 2006, 190 (425) : 8072816; discussion 816, 873-876.
[ 14 ] 　Schampaert E, Cohen EA, SchluterM, et al. The Canadian study of the sirolimus2eluting stent in the treatment of patientswith long de novo lesions in small native coronary arteries (C2SIR IUS) [ J ]. J Am Coll Cardiol, 2004, 43: 1116-1127.
[ 15 ] 　Kaiser C, B runner2La RH, Buser PT, et al. Incremental cost2effectiveness of drug2eluting stents compared with a third2generation bare2metal stent in a realworld setting: randomized Basel Stent Kosten Effektivitats Trial (BASKET)[ J ]. Lancet, 2005, 366: 921-929.
[ 16 ] 　Avezum A,Makdisse M, Spencer F, et al. Impact of age on management and outcome of acute coronary syndrome: observations from the Global Registry of Acute Coronary Events (GRACE) [ J ]. Am Heart J , 2005, 149 (1) : 67-73.
[ 17 ] 　Silary C,McNeil J, Donnan G, et al. Adverse effects if low2dose asp irin in ahealthy elderly population[ J ]. Clin Pharmacol Ther, 1993, 54 (1) : 84-89.
[ 18 ] 　The Clop idogrel in Unstable Angina To Prevent Recurrent Events Trial Investigators. Effects of clop idogrel in addition to asp irin in patients with acute coronary syndromeswithout ST2segment elevation [ J ]. N Engl J Med, 2001, 345:494-502.
[ 19 ] 　Chen ZM, J iangLX, Chen YP, et al. Addition of clop idogrel to asp irin in 45 85patients with acute myocardial infarction: randomized p lacebo2controlled trial[ J ]. Lancet, 2005, 366 (9497) : 1607-1621.
[ 20 ] 　Iakovou I,Dangas G,Mintz GS, et al. Comparison of frequency of hemorrhagic stroke in patients < 75 years versus > or = 75 years of age among patients receiving glycop rotein Ⅱb /Ⅲa inhibitors during percutaneous coronary interventions[ J ]. Am J Cardiol, 2004, 93 (3) : 346-349.
[ 21 ] 　KastratiA,Mehilli J ,Neumann FJ , et al. Abciximab in patientswith acute coronary syndromes undergoing percutaneous coronary intervention after clop idogrelp retreatment: the ISAR2REACT 2 randomized trial [ J ]. JAMA, 2006, 295(13) : 1531-1538.
[ 22 ] 　Mega JL,Morrow DA, Sabatine MS, et al. Correlation between the TIM I risk score and high2risk angiographic findings in non2ST2elevation acute coronary syndromes: observations from the Platelet Recep tor Inhibition in Ischemic Syndrome Management in Patients L imited by Unstable Signs and Symp toms( PR ISM2PLUS) trial[ J ]. Am Heart J , 2005, 149 (5) : 846-850.
[ 23 ] 　Sinnaeve PR, Huang Y,Bogaerts K, et al. Age, outcomes, and treatment effects of fibrinolytic and antithrombotic combinations: findings from Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT) 23 and ASSENT23 PLUS[ J ]. Am Heart J , 2006, 152 (4) : 684. e129.
[ 24 ] 　Antman EM,Morrow DA,McCabe CH, et al. Enoxaparin versus unfractionated heparin with fibrinolysis for ST2elevation myocardial infarction [ J ]. N Engl JMed, 2006, 354: 1477-1488.
[ 25 ] 　Krumholz HM, RadfordMJ ,Wang Y, et al. National use and effectiveness of beta2blockers for the treatment of elderly patients after acute myocardial infarction:National Cooperative Cardiovascular Project [ J ]. JAMA, 1998, 280 ( 7 ) :623-629.
[ 26 ] 　W ienbergen H, ZeymerU, GittAK, et al. Prognostic impact of acute beta2blocker therapy on top of asp irin and angiotensin2converting enzyme inhibitor therapy in consecutive patients with ST2elevation acute myocardial infarction [ J ].Am J Cardiol, 2007, 99 (9) : 1208-1211.
[ 27 ] 　Ferrari R. Effects of angiotensin2converting enzyme inhibition with perindop rilon left ventricular remodeling and clinical outcome: results of the randomizedPerindop ril and Remodeling in Elderlywith AcuteMyocardial Infarction ( PREAM I) Study[ J ]. Arch InternMed, 2006, 66 (6) : 659-666.
[ 28 ] 　Shepherd J ,B lauw GJ ,MurphyMB, et al, Pravastatin in elderly individuals atrisk of vascular disease ( PROSPER) : a randomised controlled trial [ J ]. Lancet, 2002, 60 (9346) : 1623-1630.
[ 29 ] 　Austin PC,MamdaniMM. Impact of the p ravastatin or atorvastatin evaluation and infection therapy2thrombolysis in myocardial infarction 22 /Reversal ofAtherosclerosiswith Aggressive L ip id Lowering trials on trends in intensive versus moderate statin therapy in Ontario, Canada [ J ]. Circulation, 2005, 12 ( 9 ) :1296-300.
[ 30 ] 　Olsson AG, Schwartz GG, Szarek M, et al, Effects of high2dose atorvastatin in patients >or = 65 years of age with acute coronary syndrome ( from the myocardial ischemia reduction with aggressive cholesterol lowering [M IRACL ]study) [ J ]. Am J Cardiol, 2007, 99 (5) : 632-635.